VALNEVA Reports Further Positive Results for Its Chikungunya Vaccine Candidate

by NASDAQ Market News May 22, 2019

NASDAQ Market News
Click here to email author

Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

Sentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)

Ads